Eurofins – Transplant Genomics Announces TRULO Registry Study to Evaluate Long-Term Clinical Outcomes in Patients Monitored with TruGraf® Testing
Mansfield, MA, April 15, 2020 — MANSFIELD, Mass., Eurofins [...]
Remote Testing Options to Support Care for Kidney Transplant Recipients
March 18, 2020 — Eurofins is committed to supporting [...]
Transplant Genomics, Inc. Appoints Dr. John Holman as VP Medical Affairs
Mansfield, MA, January 10, 2020 —MANSFIELD, Mass., Transplant Genomics, Inc. (“TGI”), [...]
A Practical Guide to the Clinical Implementation of Biomarkers for Subclinical Rejection Following Kidney Transplantation
Transplantation: April 2020 - Volume 104 - Issue 4 - p [...]
Transplant Genomics, Inc. Founders Awarded US Patent Covering Detection of “Silent” Sub-Clinical Rejection in Stable Kidney Transplant Recipients
Mansfield, MA, October 29, 2019 — MANSFIELD, Mass., Transplant Genomics, Inc. [...]
Transplant Genomics, Inc. Confirms TruGraf® Will Receive Medicare Coverage Effective November 25, 2019
Mansfield, MA, October 11, 2019 — Transplant Genomics, Inc. (“TGI”), a molecular [...]
Application of TruGraf v1: A Novel Molecular Biomarker for Managing Kidney Transplant Recipients With Stable Renal Function
Transplantation Proceedings Volume 51, Issue 3, April 2019, Pages 722-728 [...]
Investigator Assessment of the Utility of the TruGraf Molecular Diagnostic Test in Clinical Practice
Transplant Proc. 2019 Apr;51(3):729-733. doi: 10.1016/j.transproceed.2018.10.024 First MR, Peddi VR, [...]
Medicare Issues Draft Local Coverage Determination (LCD) for Transplant Genomics’ TruGraf® Blood Test as Alternative to Surveillance Biopsies
Mansfield, MA, March 29, 2019 — Transplant Genomics Inc. (TGI) announces [...]
Development and Clinical validity of a novel blood-based molecular biomarker for sub-clinical acute rejection following kidney transplant
American Journal of Transplantation First published: 09 July 2018 https://doi.org/10.1111/ajt.15011 [...]